About EBIOCAT™

Built on Science. Driven by Impact.

EBIOCAT™ was founded on a single conviction: that the gap between what active ingredients promise and what the body actually absorbs is a solvable problem — and that solving it at scale would transform the efficacy of health products worldwide.

Mission

Our Mission

To make every active ingredient work harder — by engineering the enzymatic conditions that maximize bioavailability, minimize waste, and deliver measurable outcomes for manufacturers, practitioners, and consumers.

Science First

Every claim we make is backed by data. We do not formulate on tradition or trend — we formulate on mechanism, evidence, and reproducible results.

Precision Over Simplicity

Bioavailability is a complex, multi-variable challenge. We embrace that complexity and engineer solutions with the precision it demands.

Partnership as Practice

We work alongside manufacturers, formulators, and R&D teams — not as a supplier, but as a scientific partner invested in their outcomes.

Regulatory Integrity

Every component of the EBIOCAT™ platform is selected for its regulatory profile. We build for compliance from day one, not as an afterthought.

Origin

The Founding Story

EBIOCAT™ emerged from years of applied research into the fundamental limitations of oral bioavailability — a problem that affects the majority of active pharmaceutical ingredients and a significant proportion of nutraceutical compounds.

The founding team identified a critical gap: while the pharmaceutical industry had developed sophisticated delivery technologies for specific compound classes, no platform existed that could systematically address bioavailability across the full spectrum of health and wellness actives — from polyphenols and botanical extracts to BCS Class II drug compounds.

The answer was not a new molecule or a novel excipient. It was a return to biochemical first principles: the body's own digestive enzyme systems are extraordinarily effective at processing complex molecular structures. EBIOCAT™ was built to replicate, amplify, and direct that enzymatic intelligence — creating a platform that works with human physiology rather than around it.

Today, EBIOCAT™ is advancing toward commercial partnerships with nutraceutical manufacturers, pharmaceutical formulators, and functional food brands — bringing precision biocatalysis to the products that millions of people rely on for their health.

Leadership

Leadership

RS

Ramesh Srinivas

Founder & CEO

MBA

With a career spanning pharmaceuticals, nutraceuticals, and wellness formulation across EU and North American markets, Ramesh brings a rare combination of scientific fluency and commercial acumen to EBIOCAT™. He founded the company to do what he has spent his career doing — bridging the gap between rigorous science and strategic market execution, building partnerships that translate laboratory innovation into products that perform.

EBIOCAT™ is supported by a multidisciplinary team with deep expertise spanning enzymology, pharmaceutical sciences, formulation chemistry, and regulatory affairs. Full team profiles will be published ahead of our commercial launch.

Enzymology & Biochemistry

Core expertise in enzyme kinetics, substrate specificity, and biocatalytic process design — the scientific foundation of the EBIOCAT™ platform.

Pharmaceutical & Formulation Science

Applied knowledge of oral drug delivery, lipid-based systems, and GMP-compliant formulation development across nutraceutical and pharmaceutical formats.

Regulatory Affairs

In-depth experience with GRAS determination, EU Novel Food regulation, and pharmaceutical excipient qualification across FDA, EFSA, and Health Canada frameworks.

Commercial & Business Development

Proven track record in B2B health ingredient licensing, strategic partnership development, and life sciences commercialisation.

Vision

Where We Are Going

EBIOCAT™ is at the beginning of a significant commercial and scientific journey.

Current
01

Platform Validation

Completing in vitro and ex vivo validation studies across priority substrate classes. Building the evidence base for commercial partner conversations.

Near-term
02

First Commercial Partnerships

Entering licensing and co-development agreements with nutraceutical manufacturers and pharmaceutical formulators in EU and North American markets.

Mid-term
03

Clinical Evidence Generation

Partnering with academic institutions and CROs to generate human bioavailability data across key substrate categories — building the clinical dossier for premium market positioning.

Long-term
04

Platform Expansion

Extending the EBIOCAT™ enzyme library to address emerging active ingredient classes, including precision fermentation-derived compounds and next-generation botanical actives.

Work With Us

Whether you are a manufacturer seeking to enhance your formulations, an investor looking for exposure to the bioavailability science space, or a researcher interested in collaboration — we want to hear from you.